ASCO 2024 Top 5 Zanidatamab Phase 2 HER2+ Questions on Biliary Tract Cancer

For More Videos Like this Subscribe to OncologyTube eNewsletter: share.hsforms....
Dr. Shubham Pant presents the latest updates from the Phase 2 trial of zanidatamab, a bispecific HER2 antibody, in patients with HER2+ biliary tract cancer (BTC) HERIZON-BTC-01.
More Details Here:
🔬 HERIZON-BTC-01 Study Highlights:
Mechanism of Action: Zanidatamab binds to two domains on the HER2 protein (ECD2 and ECD4), leading to better receptor internalization and HER2 downregulation, enhancing its antitumor effects.
Patient Cohort: The global trial included 80 patients with HER2 2+ or 3+ BTC.
Efficacy Results: The overall response rate (ORR) is 41.3%, with the duration of response (DoR) increasing to 14.9 months and a median overall survival (OS) of 15.5 months.
Safety Profile: Most adverse events were grade 1 and 2, with diarrhea being the most common, managed effectively with anti-diarrheal agents and hydration.
Comparison to Historical Data: Zanidatamab shows a significant improvement compared to historical data for FOLFOX, which had a 5% response rate.
Future Directions:
Encouraged by these results, zanidatamab is now being tested in first-line settings combined with gemcitabine, cisplatin, and immunotherapy for HER2+ BTC.
Watch the full presentation to learn more about these promising findings and their implications for HER2+ biliary tract cancer treatment. Don't forget to like, share, and subscribe to OncologyTube for more updates!
#ASCO2024 #HER2Cancer #BiliaryTractCancer #CancerResearch #Zanidatamab #Oncology #DrShubhamPant #ClinicalTrials #OncologyTube
Funding: #JazzPharmaceuticals